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Abstract 
Purpose: To evaluate the lipid profile abnormalities and association of the GATA4 (1232 C→T) and 
NKX 2.5 (73C→T) gene polymorphisms with Dilated cardiomyopathy (DCM) among Chinese 
population. 
Methods: The blood samples were collected from the Outpatient Department (OPD) of Cardiology Unit, 
Zhengzhou Central Hospital, China  for a period of three years from 2010 – 2013. Dilated 
cardiomyopathy cases (n = 270) and healthy controls (n = 290) were genotyped using polymerase chain 
reaction (PCR), restriction fragment length polymorphism, (RFLP) denaturing high-performance liquid 
chromatography (DHPLC) and sequencing. 
Results: Evaluation of the age and sex of the patients indicated that DCM was more prevalent among 
males (71.1 %) than in females (28.9 %). Mean (± SD) values of the serum total cholesterol and serum 
LDL-cholesterol were higher in DCM patients (4.37 ± 0.16 and 3.19 ± 0.14 mmol/L, respectively) 
compared to the control group (4.29 ± 0.18 and 3.06 ± 0.19 mmol/L, respectively), while as there was 
significantly lower serum mean (± SEM) HDL-cholesterol levels in patients with DCM than in controls (p 
< 0.001).  Exon 1 region of NKX 2.5 gene was screened for variations at 73C→T keeping in view both 
parameters (age and sex) among healthy controls and DCM patients. The results indicate that the 
homozygous mutant (TT) and heterozygous mutant (CT) nucleotides were significantly higher in DCM 
patients than in controls.  Further analysis of GATA4 gene revealed that five DCM patients had 1232C/T 
variant, whereas, it was absent in the control group. 
Conclusion: GATA4 1232C/T and NKX 2.5 73C→T polymorphisms and high levels of serum 
triglycerides (TG) may be associated with the pathogenesis of DCM in the studied population. 
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Cardiomyopathies are the heterogeneous group 
of myocardial disorder in which heart muscle are 
inflamed, weakened and enlarged leading to 
heart failure. They are either confined to the 
heart or become as a part of generalized 
systemic disorders, often leading to progressive 
heart failure related disability or cardiovascular 
death. Dilated cardiomyopathy (DCM) is the third 
leading cause of heart failure which is ultimately 
responsible for morbidity and mortality [1]. In 
more severe cases, DCM is associated with 
congestive heart failure (CHF), which arises 
when the heart is unable to pump sufficient blood 
to meet the body tissue needs for oxygen and 
nutrients. In most of the cases genetic factors are 
responsible for development of DCM, whereas, 
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functional characterization of these genetic 
variants indicated that the diverse cardiomyocyte 
structural and signalling defects can result in 
DCM phenotype.  Earlier studies have reported 
that the cardiac transcription factor GATA4 and 
NKX 2.5 are essential for cardiac development, 
and mutations in these genes have been 
implicated in a wide variety of congenital heart 
diseases in both animal models and humans [2] 
The expression of these transcription factors 
extend a large developmental window  of 
cardiogenesis and continues in mature heart.  
However, whether this mutated GATA4 and NKX 
2.5 predisposes to sporadic DCM remains 
unclear. 
 
ATA4 (MIM  600576)  gene  encodes a zinc 
finger containing cardiac transcription factor, it 
plays an essential role in promoting development 
and differentiation of the myocardium, as well as 
in regulating survival and hypertrophic growth of 
the adult heart. Regular function of GATA4 is 
essential for cardiac morphogenesis. In vitro and 
in vivo studies in rats and mice have confirmed 
the role of GATA4 in cardiac hypertrophy [3]. 
 
During  fetal  development  GATA4  is  
expressed  in  yolk  sac  endoderm  and  cells  
that  are involved  in  heart  formation.  It 
recognizes a consensus sequence known as 
‘GATA’ motif, which is an important cis-element 
in the promoters of many genes. Human  GATA4  
is  located  on  Chromosome  8  (8p23.1-p22)  
and consists  of  6  exons [3].  GATA4 is 
expressed in the heart, gut epithelium and 
gonads. It is highly expressed in cardiomyocytes 
at different developmental stages and continues  
to express in the adult cardiac myocytes, where it 
regulates the transcription of several  structural 
and regulatory genes, including atrial natriuretic 
factor (ANF), brain natriuretic factor, carnitine 
palmitoyltransferase Ib, troponin I, troponin C, a- 
and b-myosin heavy chain which are of vital 
importance. 
 
NKX2.5 is another essential transcription factor 
expressed in cardiac precursor cells, crucial for 
heart development and determination of 
myocardiocytel fate. The functional significance 
of NKX 2.5 gene for heart formation and 
development was observed both in animals and 
humans. The NKX 2.5 gene is localized to 
chromosome 5q34 and consists of 2 exons 
510bp and 1075bp in size which encodes a 324 
amino acid protein. Mutations in NKX2.5 gene 
have been implicated in diverse congenital heart 
diseases (CHD), cardiomyopathies and 
conduction defects (CD) in mouse models and 
humans. The transcription factor NKX 2-5 is 
known to have a role in heart development 
whereas its role in adult-onset heart disease is 
unknown. Hence, the present study was 
designed to assess the role of GATA4 and NKX 





Selection criteria for patient and control group 
Two hundred and seventy patients with dilated 
cardiomyopathy (n = 270), that were referred 
from the Department of Cardiology, Zhengzhou 
Central Hospital, Zhengzhou University, 
Zhengzhou China from  2010 – 2013, were 
recruited randomly for the study group. Two 
hundred and ninety (n=290) healthy volunteers 
corresponding to DCM patients in age and sex    
but with no family history of DCM and other 
associated genetic diseases were taken as 
control group. The study was carried out in 
accordance with the ethical standards approved 
by ethics committee of the Department of 
Cardiology, Zhengzhou Central Hospital, 
affiliated to Zhengzhou University, Zhengzhou, 
China. Informed and educated consent to 
participate in the study was taken from the DCM 
patients and healthy controls. Clinical diagnosis 
of DCM was based on the two dimensional 
echocardiography (ECG), demographic data, 
clinical features and other associated 
abnormalities. DCM patients within the age group 
of 40-50 years were included in the study, while 
as healthy volunteers corresponding to the same 
age group with no medical history of either heart 
diseases or other associated disorders were 
taken as control. 
 
Collection of blood samples 
 
Blood sample (5 mL) was collected from each 
subject for biochemical analysis and molecular 
screening of GATA4 and NKX2.5 gene 
mutations. Blood samples from the healthy 
controls were also collected for the analysis and 
comparison. All the samples were collected after 
prior description and consent.  
 
Measurement of biochemical variables 
 
Fasting blood samples were collected in liquid 
EDTA blood tubes, and carried on ice to 
laboratory, centrifuged, and aliquoted for storage 
in −80 °C. Fasting total cholesterol, triglyceride 
(TG), low and high density lipoprotein - 
cholesterol (LDL-C, HDL-C) were measured in 
serum of all DCM patients and healthy controls. 
The total serum cholesterol was determined by 
the enzymatic colorimetric method of Allain et al 
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[4]. Demacker et al enzymatic method was used 
for the estimation of serum HDL-C while as 
serum LDL-C was estimated by using Anwar et 
al formula [5]. Serum TG was determined 
according to the enzymatic method of Bucolo 
and David [6].  
 
Genomic DNA isolation  
 
Genomic DNA was isolated by phenol-chloroform 
method described by Blin and Stafford [7]. In 
brief, WBCs were isolated from blood samples 
using erythrocyte lysis buffer (20 mg/mL 
Proteinase K, 155 mM ammonium chloride, 7.23 
mM potassium carbonate, 0.5 M EDTA, and 20 
% SDS) and incubated at 37 oC. Then 5 mL of 
Tris equilibrated phenol (pH = 8) was added to 
the sample and centrifuged at 1000 g for 10 min. 
To the supernatant phenol: chloroform: isoamyl 
alcohol (25:24:1) mixture was added (5 mL) and 
incubated for 2 min and then centrifuged at 1000 
g for 10 min. Furthermore chloroform: isoamyl 
alcohol (24:1) was added to the supernatant (5 
mL) and centrifuged for 15 min at 1000 g. DNA 
was precipitated with absolute alcohol (chilled) 
and dissolved in Tris-EDTA buffer and stored at -
20 oC for further analysis. 
 
Testing for sequence variants 
 
NKX2.5Exon1 (489bp) of NKX2.5 gene was 
amplified by using forward primer -
5’GTCCCGCCTCTCCTGCCCCTTGTG-
3’andreverseprimer -
5’AGGGTCCTTGGCTGGGTCGG3’, in  50 μL 
containing 20 pmol each  along with 10 mM 
dNTPs, 3U Taq DNA polymerase, 100 ng of 
genomic DNA and 10X PCR buffer. The gene 
was amplified in MJ mini thermal cycler with the 
subsequent PCR conditions: the initial 
denaturation was at 95 °C for 7 min, followed by 
34 cycles of denaturation (95 °C for 30 sec), 
annealing (64.5 °C for 1min), extension (72 °C 
for 1 min) and the final extension step was set for 
72 oC for 10 min. 
 
Restriction fragment length polymorphism 
 
The PCR products from the patients and controls 
were analyzed for the variant 73C→T in the 
NKX2.5 gene using HhaI restriction enzyme for 
RFLP analysis. The reaction mixture of restriction 
enzyme digest includes restriction buffer, HhaI (3 
U), PCR product (10 µl) and sterile water (20 µl). 
The reaction mixtures were incubated at 65 oC 
for 3 h. The restriction digestion contents were 
then resolved on a 12 % PAGE (Acrylamide: 
bisacrylamide solution-29:1, 10 % glycerol, 10 % 
APS, TEMED, 10XTBE buffer) followed by 
staining (20 μg/mL) with ethidium bromide. The 
resulting restriction digestion yields 134, 90/82 
and 63 in heterozygous (CT), 134 and 63 in 
homozygous (TT) genotypes, 90/82 and 63 DNA 





For GATA4 gene, the coding region was 
segmented into exon–intron junction sequences 
suitable for DHPLC (denaturing high-
performance liquid chromatography - WAVE, 
Transgenomics Inc, USA) or CSGE analysis. The 
6th exon was amplified from genomic DNA using 
Forward - 5’ CCTAGACCTCCCAAGC 3’ 
Reverse 5’GGCCTCCTTCTTTGCTATCC 3’ 
primers. The PCR containing  20 ng genomic 
DNA was  amplified in a 30 µl reaction mixture 
containing 1.5 U HotStar Taq polymerase and 16 
HotStar Taq PCR Buffer (Qiagen Inc., California, 
USA), 125 mmol/l of each dNTP (Roche, 
Germany), 1.5 mmol/l MgCl2, and 1 mmol/l of 
each PCR primer. The reactions started with 5 
min at 95 oC followed by 37 – 40 cycles of 45 s at 
95 oC, 30 sec at 61 oC and 45 sec at 72 oC, and 
finished with a 15-min extension period at 72 oC. 
PCR products were then examined for sequence 
alterations by DHPLC and sequencing analysis. 
Samples that showed peak or band shifts were 
re-amplified from the genomic DNA and 
sequenced in both directions with an automated 
cycle sequencer (ABI BigDye Taq FS Terminator 
V.3.1; ABI Prism 3100sequencer, Applied 




Statistical analysis was performed with Plink 
software. For evaluation of markers, whether 
they are in hardy Weinberg equilibrium, and for 
association analysis, a cut-off p < 0.01 was used. 
The significance was assessed by Analysis of 
variance (ANOVA) and Student t-test. The χ2 test 
was applied to determine the cited equilibrium. 
Logistic regression analysis was employed to 
determine the risk of dilated cardiomyopathy, 
including age and sex as intervening variables. P 
< 0.05 was considered significant. The final 
results were shown as odd ratio with the 




Two hundred and seventy (n=270) dilated 
cardiomyopathy (DCM) patients and two hundred 
and ninety (n = 290) healthy controls were 
analyzed for the variation in lipid profile and gene 
polymorphisms in NKX2.5 73C→T by RFLP-
PAGE using Hha1 and GATA4 by 
DHPLC/sequencing methods (Figure 1). 
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Characteristics of the DCM patients and controls 




Figure 1: Partial sequence of GATA4 (exon 6) 
showing overlapping of T and C bases (reverse 
strand) indicating the alternation between normal and 
polymorphism sequence 
 
The mean age at diagnosis was 45.7 years in 
male cases and 48.2 years in female cases. 
Compared to the controls, the cases were 
shorter by approximately 1 cm (p < 0.05) and 
had higher alcohol consumption habits (p < 
0.001) (Table 2). Transplanted patients were 
younger in age, leaner and had lower alcohol 
consumption habits than the non-transplanted 
patients, and they were characterized by a more 
severe left ventricular dysfunction and a lower 
ejection fraction (data not shown). 
 
The evaluation of the age and sex frequency of 
the patients with DCM indicate that DCM was 
more prevalent among males (71.1 %) than in 
females (28.9 %). The general characteristics of 
DCM patient’s associated heart defects and 
inheritance are represented in the Table 1-3. The 
mean (± SD) values of the serum total 
cholesterol and serum LDL-cholesterol were 
found to be  higher in the DCM patients (4.37 ± 
0.16 mmol/L; 3.19 ± 0.14 mmol/L, respectively) 
than in the control group (4.29 ± 0.18 mmol/L; 
3.06 ± 0.19 mmol/L, respectively) (Tables 1 and 
2).
 
Table 1:  Characteristics of the cases and controls 
 












Age (yr)* 45.7 (0.5) 46.3 (0.5) 48.2 (1.0) 48.7 (1.1) 0.34 
Height (cm) 172.6 (0.4) 173.3 (0.4) 161.2 (0.6) 162.4 (0.7) 0.02 
Weight (kg)  74.3 (0.7) 75.7 (0.7) 59.6 (1.4) 62.1 (1.5) 0.14 
BMI (kg/m2)  25.5 (0.2) 25.5 (0.2) 23.3 (0.4) 23.6 (0.5) 0.59 
Alcohol (g/day)  79.3 (3.1) 26.4 (3.2) 8.7 (6.2) 11.9 (6.8) 0.001 
Age at diagnosis for cases and current age for controls. Data are expressed as mean (± SE) or %. BMI = body 
mass index (weight/height2) 
 
Table 2: The baseline clinical characteristics of the subjects under study 
 
Variable PT (n=270) Control (n=290) 
Age (years) 47.2 ± 12.7 48.5 ± 13.6 
Male (%)   192 (71.1) 218 (75.2) 
Females (%) 78 (28.9) 72 (24.8) 
Family history of DCM (%) 42 (38.2) 0 (0) 
SBP (mmHg)   114.5 ± 15.1 119.3 ± 11.9 
DBP (mmHg)   71.8 ± 7.5 81.4 ±5.2 
HR (bpm) 107.2 ± 13.5 76.2 ± 10.3 
LVEDD (mm) 70.3 ± 9.3 47.5 ± 5.1 
LVESD (mm)   55.7 ± 7.4 33.1 ± 4.3 
LVEF (%) 34.8 ± 8.4 61.5 ± 7.5 
NYHA function class (%) 
I 43 (15.9) NA 
II 108 (40) NA 
III 93 (34.4) NA 
IV 26 (9.7) NA 
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There was a significantly low serum mean (± 
SEM) HDL-cholesterol level in patients with DCM 
against the controls (0.84 ± 0.03 mmol/L, 0.99 ± 
0.03 mmol/L; p < 0.001, respectively, Table 3). 
 
The mean (± SEM) serum TG levels in DCM 
patients (1.82 ± 0.14 mmol/L) were  significantly 
higher  compared to  normal controls (1.25 ± 
0.14, p < 0.05) (Table 4). 
 
In the present study, exon 1 region of NKX 2.5 
gene was screened for variation 73C→T in both 
age-sex matched healthy controls and DCM 
patients. The results indicated that the nucleotide 
variation of NKX 2.5 gene is significantly 
associated with the DCM patients compared to 
the controls (Table 5). 
 
In Figure 2, the PAGE gel picture represents the 
presence of all three genotypes in which the 
mutant genotypes are more specific for DCM. 
The NKX2.5 73C→T mutation results in the 
substitution of Arg25Cys (arginine to cystein) at 
residue 25 of the protein. 
 
 
Figure 2: Amplification of NKX 2.5 Gene (exon 1). 
Lane M: 100bp Marker, Lane 1-4: PCR products of 
patients,   Lane 5-7: PCR products of controls 
Table 3: Phenotypic characteristics of the affected living pedigree members 
 








LVEF (%) ECG 
findings 
III-4  F  50 DCM 73.2 61.4 35.1  
III-7  M  46 DCM, ASD 64.5 52.4 43.2 AF 
IV-2 M  41 DCM 57.2 47.3 43.7 AVB 
IV-4  F  43 DCM, ASD 59.1 48.7 37.9  
 
Table 4: Mean (± SEM) serum values of total Cholesterol, LDL-Cholesterol, HDL-Cholesterol and Triglyceride in 
controls and patients with IDC 
 
Variable Control DCM P-value 
Total cholesterol(mmol/L) 4.29 ± 0.18 4.37 ± 0.16 P>0.05 
LDL-C (mmol/L) 3.06 ± 0.19 3.19 ± 0.14 P>0.05 
HDL-C (mmol/L) 0.99 ± 0.03 0.84 ± 0.03 P< 0.001 
TG (mmol/L) 1.25 ± 0.14 1.82 ± 0.14 P< 0.05 
 










































C vs. T 
CC vs. TT 
CC vs. CT 
CC vs. TT + CT 
 
 












Figure 3: Restriction Fragment Length Polymorphism of NKX 2.5 Gene (Exon 1). Lane M; 1000bp Marker, Lane 
1: PCR Product, Lane 2: Heterozygous CT Mutation of patients, Lane 3, 5: Wild type fragment of patients, Lane 
4: Homozygous TT of patient, Lane 6,7: Wild type fragment of controls 
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Furthermore, we also investigated the genomic 
DNA of the DCM patients for variations in exon 6 
of the GATA4 gene. Our analysis revealed that 
the five DCM patients showed 1232C/T variant, 
whereas it was absent in the controls resulting in 
Ala411Val change in the protein. The patients 
carrying the 1232C/T variant did not show family 
history of cardiomyopathy or any other heart 
defects. 
 
In addition we investigated whether the 
polymorphisms were associated with the severity 
of the disease when assessed by the ejection 
fraction (,/$24 %), left ventricular dilation (end-
diastolic diameter ,/$40 mm/m2) or heart 
transplantation. The genotype and allele 
frequencies did not differ between patients with 
or without a familial history of DCM.  As we know 
that alcohol intake is a major etiologic factor for 
DCM, we tried to investigate whether alcohol 
may modulate the effect of polymorphisms on the 
risk of DCM, but we did not found  any evidence 




Dilated cardiomyopathy (DCM) is a myocardial 
disorder that leads to congestive heart failure 
and sudden cardiac death. It is an indication for 
cardiac transplantation in patients due to 
ventricular chamber enlargement and contractile 
dysfunction [8]. Nearly 50 % of DCM cases are 
idiopathic and 20-30 % cases are familial. 
Functional characterization studies indicated that 
the genetic and environmental risk factors play 
an important role in the pathogenesis of DCM.  
 
Lipids play an important role in cardiovascular 
disease complications and there are very few 
studies on lipid abnormalities in the prevalence of 
DCM. The observations of the present study 
indicated that the dilated cardiomyopathy 
patients had significantly lower HDL-C level and 
markedly higher TG concentrations than healthy 
subjects and the results are consistent with the 
reports of Cooke et al who demonstrated that the 
mean serum HDL cholesterol serum levels of 
congestive heart failure (CHF) patients were 
significantly lower than that of normal subjects 
(0.86 ± 0.24 and 1.2 ± 0.31 mmol/L, 
respectively). The present study is in contrast 
with the results of Freitas et al [9] who reported a 
higher serum HDL cholesterol levels in heart 
failure patients.  
 
Similarly, Basil et al [10] also observed no 
statistical differences between the serum total 
cholesterol and LDL-cholesterol levels of the 
idiopathic dilated cardiomyopathy patients 
compared to the normal controls. Elevated serum 
LDL-cholesterol levels are fundamentally related 
to ischemic heart disease (IHD) and its reduction 
reduces the incidence of IHD and the associated 
mortality rate. Basil et al [10] also reported that 
HDL-cholesterol functions as an autonomous 
protective factor for the endothelium. It has been 
observed that HDL-cholesterol induces the 
activation of endothelial NO synthase, NO 
release, and vasorelaxatory effects [8,11]. Earlier 
studies have reported that increased levels of 
serum triglycerides are associated with heart 
failure and our results also demonstrates a 
statistically significant relationship between 
serum triglycerides and mortality. [12,13].  
 
Several genetically engineered models for dilated 
cardiomyopathy have been reported recently, to 
explain the role of genes/transcription factors in 
the development of the disease [14]. A recent 
study has implicated GATA4 gene mutation in 
the pathogenesis of familial DCM [15,16]. 
Functional analysis demonstrates that the 
GATA4 mutation was significantly associated 
with the decreased transcriptional activity and 
remarkably reduced synergistic activation 
between GATA4 and NKX2-5, another 
transcription factor is crucial for cardiogenesis 
and the functioning of the heart [17]. GATA4 may 
bind to the target DNA in association with other 
partners including NKX2-5, and the synergistic 
transcriptional activation mediated by NKX2-5 
has been verified [18,19]. However there are no 
reports on the GATA4 1232 C→T and NKX2.5 
73C→T gene polymorphisms yet. Therefore, the 
present study was carried out to analyze the 
frequency of GATA4 and NKX 2.5 gene 
polymorphisms in patients suffering from dilated 
cardiomyopathy. The current study indicates that 
the five DCM patients had 1232C/T variant, 
whereas it was absent in the control group 
(Figure 3). The patients carrying the 1232C/T 
variant did not show family history of 
cardiomyopathy or any other heart defects. 
Among the various polymorphisms of the GATA4 
gene, it is now evident that in exon 6, the 
1232C/T variant has important implications in the 
etio-pathogenesis of cardiovascular diseases 
and DCM being a complex disorder associated 
with heart failure may be one of such CVD with 
the underlying mechanism of oxidative stress. 
 
GATA4 is a transcription factor that belongs to 
the GATA family of zinc finger proteins 
expressed in various organs including the 
hematopoietic system, the heart, the gonads, the 
lungs, and the kidneys [20]. The C-terminal finger 
acts as a DNA-binding domain and it interacts 
with other transcription factors such as NKX2.5 
and TBX5. The N-terminal domain helps in 
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stabilizing DNA binding [19,21]. In vitro and in 
vivo studies in rats and mice have confirmed the 
role of GATA4 in cardiac hypertrophy. Loss of 
function mutation of GATA4 in mice resulted in 
their inability to undergo physiological 
hypertrophy during pressure overload.  
 
GATA4 is also found to be associated with 
hypertrophic cardiomyopathy caused by 
cardiomyocyte hyper-proliferation without 
hypertrophy [14] In a recent study, Li et al [16 ] 
reported an autosomal dominant missense 
mutation (c.812G > C) that results in a p.C271S 
substitution in the amino acid sequence in DCM 
patients with 100 % penetrance. Similarly, Zhao 
et al [1] also demonstrated an autosomal 
dominant novel heterozygous GATA4 mutation 
(p.V291L) in DCM. 
 
Cardiac transcription factors GATA4 and NKX 
2.5 are the essential transcriptional factors 
expressed predominantly in the heart and they 
regulate the expression of the cardiac genes 
encoding structural proteins [22]. Zhao et al [1] 
reported genetic polymorphisms in GATA4 and 
NKX2.5 genes as potential transcriptional factors 
of hypertrophic and dilated cardiomyopathy 
phenotypes. Yuan et al [23] observed a novel 
NKX2-5 loss-of-function in familial dilated 
cardiomyopathy and arrhythmias patients.  
Similar findings were observed in the present 
study. An increased frequency of 73C→T variant 
was detected in the DCM patients. The 
prevalence of variation in the present study was 
found to be 4.4 % in homozygotes (TT) and 29.4 
% in heterozygous patients (CT) compared to the 
controls (TT-0.7 %: CT-8.6 %).  Similarly, Yuan 
et al [23] also reported p.S146W polymorphism 
in a family with DCM which was inherited as an 
autosomal dominant trait and co-segregated with 
DCM in the family with complete penetrance. 
Pashmforoush et al [24] observed that the Nkx2-
5 mutations leads to progressive cardiomyopathy 
and conduction defects. 
 
NKX2-5 is crucial for heart development and 
mutations in this gene is implicated in diverse 
congenital heart diseases and conduction 
defects in mouse models and humans [7]. 
NKX2.5 is the earliest known marker for 
myocardial progenitor cells in all species in which 
it has been studied. Previous reports have 
described the NKX2.5 mutations in various 
congenital heart defects [25]. The nucleotide 
variation 73C→T corresponds to change from 
arginine to cysteine (Arg25Cys) at residue 25 in 
the protein of NKX2.5 transcription factor 
resulting in the charge of an amino acid from 
basic to neutral and is highly conserved between 
species.  Arg25Cys is a missense mutation and 
is present outside the homeodomain region in 
the amino terminus of the non-homeodomain 
region. Arg25 residue does not lie within a 
functional domain of NKX2-5, according to 
secondary structure prediction with the protein 
forecasting (PROF) algorithm. Arg25 is just 
outside the first helix region of NKX2-5 spanning 
residues 14 to 24. The highly charged nature of 
arginine also dictates solvent accessibility. 
Mechanistically, NKX2.5 seems to be regulating 
precise target gene activation at each 
developmental stage and the mutations in 
NKX2.5 could not bind to the other transcription 





The present study indicates that GATA4 and 
NKX2.5 mutations may be penetrant with 
variable expressivity in the DCM patients. The 
higher frequency of the mutant alleles/genotypes 
and the abnormal lipid profile in the present study 
may be due to genetic diversity and ethnic 
variation. Hence, GATA4 and NKX2.5 are 
possible candidate genes in the athogenesis of 
DCM. Furthermore, identification and screening 
of mutations will provide insight into the potential 
role of the GATA4 and NKX2.5 genes in the 
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